A Randomised Control Study Comparing Intradermal Tranexamic Acid and Intradermal Platelet-Rich Plasma For The Treatment Of Melasma

Intradermal Tranexamic Acid Vs Intradermal Platelet-Rich Plasma In The Treatment Of Melasma- A Randomised Control Study - nil

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/08/092525

Enrollment

Registered

2025-08-06

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

Intervention1: Intradermal Platelet Rich Plasma (PRP): PRP will be used for the treatment of Melasma over a period of 4 months. It is a relatively newer treatment modality for melasma. Control Interve

Eligibility

Inclusion criteria

Inclusion criteria: ADULT PATIENTS WITH EPIDERMAL OR DERMAL OR MIXED MELASMA.

Exclusion criteria

Exclusion criteria: Patients who have used any form of melasma treatment, whether oral or topical, within the previous 3 months. Patients with established platelet dysfunction disorder. Patients on oral contraceptive pills. Known cases of bleeding disorders. Pregnant women. Breastfeeding females. Patients on anticoagulants.

Design outcomes

Primary

Measure	Time frame
Pain Erythema InflammationTimepoint: 1, 2, 3, 4, 7 MONTHS	—

Secondary

Measure	Time frame
Hypopigmentation Recurrence Post inflammatory hyperpigmentationTimepoint: 7 MONTHS	—

Countries

India

Contacts

Public ContactDr Simran Jain

Krishna Mohan Medical College and Hospital

dr_bumb@rediffmail.com9811105831

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026